If they get green light from FDA for AA pathway, they will submit the BLA application for Revascor by the end of this year and if approved, by the second half of 2026 they can start the commercialisation of Revescor while they are running the confirmatory trial. So I would say in about 18 months we can start selling Revascor for ischemic heart failure in patients with high inflammation. Much bigger market than SR-aGvHD.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.030(1.85%) |
Mkt cap ! $2.108B | |||
| Open | High | Low | Value | Volume |
| $1.64 | $1.67 | $1.63 | $4.884M | 2.962M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 10583 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 16415 | 4 |
View Market Depth
| Last trade - 16.12pm 27/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |